Investigators said that the OLE study showed Roche’s gantenerumab dropped the risk of developing Alzheimer's symptoms by 50%.

Lilly isn't alone in this, Danish drugmaker Novo Nordisk - which markets blockbuster weight loss drug Ozempic - too had ...

GLP-1 agonists remain out of reach for many due to high costs, leading some patients to turn to unsafe compounded versions ...

As research continues, Mounjaro may redefine medical weight loss strategies, but its ethical implications and long-term effects must be carefully monitored.

Mounjaro is approved as an adjunct to a reduced-calorie diet and increased physical activity for adults with an initial body mass index (BMI) of 30 kg/m² or greater (obesity) or 27 kg/m² or greater ...

Eli Lilly and Company (India) on Thursday said it has launched a first-of-its-kind medication for obesity and type 2 diabetes ...

REGIONS NEWS Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 SYX-5219 is a first-in-class oral PKM2 modulator designed to drive ...

Eli Lilly has launched its blockbuster diabetes and weight-loss drug Mounjaro in India following approval from the country’s ...

Mounjaro is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly has launched Mounjaro in India, a new once-weekly injectable drug for type 2 diabetes and weight management.